Phase III news from FierceBiotech
NewsRoche posts new data backing Actemra for RA
Roche has racked up more late-stage data backing Actemra as a new therapy for rheumatoid arthritis. Researchers say their fifth Phase III trial demonstrated that the therapy inhibited structural Read more...
SPOTLIGHT: FDA OKs expanded access for stem cell therapy
Osiris Therapeutics has won approval for an expanded access treatment program for Prochymal, making the Phase III stem cell therapy for graft-vs-host-disease available to children. Read more...
Report: Wilex, GPC nearing merger pact
Two German biotech companies which share a very big investor are preparing to merge, according to a prominent German newspaper. Wilex and GPC Biotech, both involved in developing new cancer Read more...
NicOx shares plunge on Pfizer trial failure
Shares of France's NicOx tumbled 38 percent after Pfizer announced that it would not advance their Read more...
Valeant chops workforce in restructuring
In an effort to bring expenses in line with revenues, Valeant is cutting 130 workers in the U.S. and Mexico. In addition, headcount will be further reduced by 1,250 positions as it divests its Read more...
Mass. biotechs ripe for buyouts
Recently, GSK forked over $720 million for Sirtris Pharmaceuticals and Japan's Takeda made an Read more...
Dyax forges $231M development deal for DX-88
Cubist Pharmaceuticals has agreed to pay Dyax $15 million upfront and up to $216.5 million more in potential milestone payments for collaboration rights to Dyax's experimental therapy for the Read more...
Drug work completed, Theravance cuts 40% of staff
Theravance announced that it is cutting 40 percent of its workforce now that it has finished work on its antibiotic telavancin. Telavancin is currently undergoing FDA review: in March the FDA Read more...
Inspire abandons nasal spray after drug flunks trial
Disappointed by lackluster data, Inspire Pharmaceuticals has abandoned development of its epinastine nasal spray for the treatment of seasonal allergic rhinitis. Subjects treated with the nasal Read more...
SPOTLIGHT: Replydine halts Phase III to conserve cash
Replidyne has stopped enrollment in its Phase III trial of faropenem, a chronic bronchitis treatment. The company said the move is designed to "conserve its cash assets and support initiatives Read more...
| Press ReleasesPRESS RELEASE: MediQuest Announces Positive Results from Phase III Study MediQuest Announces Positive Results from Phase III Study Trial Holds Promise for Millions Suffering from Raynaud's Disease BOTHELL, WA - Nov. 8, 2007 - MediQuest Therapeutics today announced that Read more... PRESS RELEASE: Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis BOSTON, Nov. 7 -- Patients with active psoriatic Read more... PRESS RELEASE: Novacea Halts Late-Stage Trial of Prostate Cancer Drug Asentar Novacea Halts Late-Stage Trial of Prostate Cancer Drug Asentar SOUTH SAN FRANCISCO, CA - Nov 5, 2007 -- Novacea announced today that the company has ended its Phase 3 ASCENT-2 clinical trial of Read more... PRESS RELEASE: GPC Biotech and Pharmion Announce Results of Overall Survival Analysis from the Satraplatin Pivotal Phase 3 Trial GPC Biotech and Pharmion Announce Results of Overall Survival Analysis from the Satraplatin Pivotal Phase 3 Trial • Overall survival results do not achieve statistical significance • GPC Biotech Read more... PRESS RELEASE: Sirion Therapeutics Announces Positive Phase III Results for Difluprednate Sirion Therapeutics Announces Positive Phase III Results for Difluprednate TAMPA, Fla., Oct. 25 -- Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced Read more... |
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight